MARKET

DXCM

DXCM

DexCom
NASDAQ

Real-time Quotes | Nasdaq Last Sale

560.74
-11.99
-2.09%
After Hours: 560.74 0 0.00% 17:35 09/24 EDT
OPEN
570.91
PREV CLOSE
572.73
HIGH
572.04
LOW
558.00
VOLUME
438.34K
TURNOVER
--
52 WEEK HIGH
579.00
52 WEEK LOW
305.63
MARKET CAP
54.25B
P/E (TTM)
105.02
1D
5D
1M
3M
1Y
5Y
Desperate for Solutions, Diabetes and Obesity Healthcare Sectors Find Answers, Hope in Innovative Tech
/PRNewswire/ -- Navigating today's healthcare systems can be overwhelming. Outrageous costs combined with complex processes have created a healthcare system renowned for overpriced inefficiency; PolicyAdvice reported that in 2018, the global healthcare mar...
PR Newswire - PRF · 1d ago
Dexcom Insider Sold Over $3.24 Million In Company Stock
Kevin R Sayer, CEO And President at Dexcom (NASDAQ:DXCM), made a large insider sell on September 15, according to a new SEC filing.
Benzinga · 09/17 14:16
Dexcom Inc (DXCM) Chairman, CEO & President Kevin R Sayer Sold $3.2 million of Shares
GuruFocus News · 09/17 13:15
Insider Sell: Dexcom
MT Newswires · 09/17 09:24
BlackRock Series Fund, Inc. Buys Johnson & Johnson, Qualcomm Inc, MetLife Inc, Sells Cisco ...
GuruFocus News · 09/17 04:38
Expert Ratings For DexCom
Within the last quarter, DexCom (NASDAQ:DXCM) has observed the following analyst ratings:
Benzinga · 09/16 17:22
Midday Report: US Stocks Drop While Yields Jump Following Mixed Economic Data
MT Newswires · 09/16 13:34
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $650
Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $550 to $650.
Benzinga · 09/16 10:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DXCM. Analyze the recent business situations of DexCom through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DXCM stock price target is 530.60 with a high estimate of 650.00 and a low estimate of 475.00.
EPS
Institutional Holdings
Institutions: 922
Institutional Holdings: 104.99M
% Owned: 108.52%
Shares Outstanding: 96.75M
TypeInstitutionsShares
Increased
304
8.43M
New
79
1.05M
Decreased
199
5.16M
Sold Out
76
569.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Sayer
Chief Financial Officer/Executive Vice President
Jereme Sylvain
Chief Operating Officer
Quentin Blackford
Chief Human Resource Officer/Executive Vice President
Sadie Stern
Executive Vice President/Chief Technology Officer
Jacob Leach
Executive Vice President
Donald Abbey
Executive Vice President
Andrew Balo
Executive Vice President
Paul Flynn
Executive Vice President
Patrick Murphy
Executive Vice President
Chad Patterson
Executive Vice President
Barry Regan
Senior Vice President/Chief Risk Officer
Sumi Shrishrimal
Senior Vice President
Shelly Selvaraj
General Manager
Steven Pacelli
Lead Director/Independent Director
Mark Foletta
Independent Director
Steven Altman
Independent Director
Nicholas Augustinos
Independent Director
Richard Collins
Independent Director
Karen Dahut
Independent Director
Bridgette Heller
Independent Director
Barbara Kahn
Independent Director
Kyle Malady
Independent Director
Jay Skyler
Independent Director
Eric Topol
No Data
About DXCM
Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Webull offers kinds of DexCom, Inc. stock information, including NASDAQ:DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.